Search for: "Mylan Pharmaceuticals"
Results 461 - 480
of 739
Sorted by Relevance
|
Sort by Date
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent… [read post]
22 Jul 2009, 6:05 am
(PatLit) Levaquin (Levofloxacin) – US: CAFC awards only partial costs where depositions used in multiple cases from different district courts: Ortho-McNeil Pharmaceutical, Inc. v. [read post]
29 Jun 2010, 6:01 pm
Mylan Pharmaceuticals Inc. et al. [read post]
30 Jun 2010, 5:52 am
Mylan Pharmaceuticals Inc. et al. [read post]
15 Jun 2011, 4:56 am
Mylan Inc. et al. [read post]
21 Sep 2011, 6:41 am
Mylan Bertek Pharmaceuticals, Inc., Civil No. 09-690 (JNE/JSM), 2010 WL 2519988 (D. [read post]
6 Nov 2015, 6:58 am
Mylan and Actavis were seeking revocation of the patent. [read post]
13 Jul 2021, 6:11 am
Court of Appeal of Brussel, 5 May 2020, Mylan BVBA v. [read post]
7 Dec 2021, 8:33 am
Mylan Pharms. [read post]
6 Feb 2019, 5:00 am
I suppose a more salient example is Mylan's Epi-Pen, which uses a protected delivery system for a generic drug. [read post]
18 Aug 2010, 12:19 am
Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind. [read post]
18 Jul 2012, 4:52 am
In the pharmaceutical field, for example, a patent can be granted based on in vitro results. [read post]
19 Mar 2012, 1:31 am
Mylan Pharms., Inc., No. 0247 (Phil. [read post]
21 Oct 2014, 12:00 am
Other recent pharmaceutical cases concerning inventive step There have been several cases in recent times where inventive step been determined in the context of a pharmaceutical invention. [read post]
12 Oct 2010, 8:56 pm
Highlights this week included: Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. [read post]
21 Jan 2011, 6:38 am
Senate (see our previous posts here and here) critical of the Agency’s recent characterization of the 12-year reference product exclusivity period provided by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) as “marketing exclusivity” rather than “data exclusivity,” several generic drug manufacturers (Hospira, Momenta Pharmaceuticals, Hospira, Mylan Labs, Teva Pharmaceuticals, and Watson… [read post]
11 May 2011, 4:54 am
ARUP: Genetic testing patents found to be anticipated and in violation of Lilly written description requirement (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O) US: FDA gets the ball rolling on biosimilar/interchangeable biological product user fee program; proposal gives a hat tip to PDUFA while acknowledging the nascent state of the industry (FDA Law Blog) (Patent Docs) Products Citalopram – UK Patents Court disapproving of EPO’s approach to assessment of novelty: Lundbeck v… [read post]
19 Dec 2008, 1:00 pm
$16.8 million for Alphapharm and Mylan: Takeda v Mylan (Patent Baristas) (Patent Docs) Boniva (Ibandronic acid) – US: Apotex challenges validity of Hoffmann-La Roche’s Boniva patent (Law360) Boniva (Ibandronic acid) – US: Orchid Chemicals & Pharmaceuticals and Orgenus Pharma seek declaratory judgment of invalidity and noninfringement in patent infringement suit brought by Hoffmann-La Roche over Boniva (Law360) Cardizem (Diltiazem)… [read post]
24 Mar 2010, 4:45 am
Synthon Pharmaceuticals, Inc. [read post]
30 Apr 2008, 2:18 pm
In more detail, according to this Digitek MedWatch Safety Alert: The products are distributed by Mylan Pharmaceuticals Inc., under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label. [read post]
